Document is current
Any future updates will be listed below
-
Authors
Singh, Prince https://orcid.org/0000-0002-9486-6002
Harris, Peter C.
Sas, David J.
Lieske, John C. https://orcid.org/0000-0002-0202-5944
- License Information
-
More Information
Article History
Accepted: 17 November 2021
First Online: 14 December 2021
Competing interests
: J.C.L. receives consulting fees from the American Board of Internal Medicine, Alnylam, OxThera, Dicerna, Synlogic, Orfan and Novobiome, and grant support from Alnylam, Allena, Retrophin, OxThera, NIDDK and Dicerna. D.J.S. has received consulting fees from Advicenne, and lecture fees from Retrophin. P.C.H. receives consulting fees from Otsuka Pharmaceuticals, Mitobridge, Regulus, Vertex Pharmaceuticals and Caraway Therapeutics. He has received grant support from Otsuka Pharmaceuticals, Navitor, Acceleron and Jemincare. P.S. has no competing interests.
